486 related articles for article (PubMed ID: 32957646)
1. The Implementation of Mass Spectrometry-Based Proteomics Workflows in Clinical Routines of Acute Myeloid Leukemia: Applicability and Perspectives.
Hernandez-Valladares M; Bruserud Ø; Selheim F
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957646
[TBL] [Abstract][Full Text] [Related]
2. Freezing effects on the acute myeloid leukemia cell proteome and phosphoproteome revealed using optimal quantitative workflows.
Aasebø E; Mjaavatten O; Vaudel M; Farag Y; Selheim F; Berven F; Bruserud Ø; Hernandez-Valladares M
J Proteomics; 2016 Aug; 145():214-225. PubMed ID: 27107777
[TBL] [Abstract][Full Text] [Related]
3. Performance of super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines.
Aasebø E; Vaudel M; Mjaavatten O; Gausdal G; Van der Burgh A; Gjertsen BT; Døskeland SO; Bruserud O; Berven FS; Selheim F
Proteomics; 2014 Sep; 14(17-18):1971-6. PubMed ID: 25044641
[TBL] [Abstract][Full Text] [Related]
4. Proteogenomics approaches for studying cancer biology and their potential in the identification of acute myeloid leukemia biomarkers.
Hernandez-Valladares M; Vaudel M; Selheim F; Berven F; Bruserud Ø
Expert Rev Proteomics; 2017 Aug; 14(8):649-663. PubMed ID: 28693350
[TBL] [Abstract][Full Text] [Related]
5. Global Cell Proteome Profiling, Phospho-signaling and Quantitative Proteomics for Identification of New Biomarkers in Acute Myeloid Leukemia Patients.
Aasebø E; Forthun RB; Berven F; Selheim F; Hernandez-Valladares M
Curr Pharm Biotechnol; 2016; 17(1):52-70. PubMed ID: 26306748
[TBL] [Abstract][Full Text] [Related]
6. Perspectives of proteomics in acute myeloid leukemia.
Czibere A; Grall F; Aivado M
Expert Rev Anticancer Ther; 2006 Nov; 6(11):1663-75. PubMed ID: 17134369
[TBL] [Abstract][Full Text] [Related]
7. Analytical validation considerations of multiplex mass-spectrometry-based proteomic platforms for measuring protein biomarkers.
Boja ES; Fehniger TE; Baker MS; Marko-Varga G; Rodriguez H
J Proteome Res; 2014 Dec; 13(12):5325-32. PubMed ID: 25171765
[TBL] [Abstract][Full Text] [Related]
8. Proteomics approaches for myeloid leukemia drug discovery.
Kapoor I; Pal P; Lochab S; Kanaujiya JK; Trivedi AK
Expert Opin Drug Discov; 2012 Dec; 7(12):1165-75. PubMed ID: 22971110
[TBL] [Abstract][Full Text] [Related]
9. High throughput and accurate serum proteome profiling by integrated sample preparation technology and single-run data independent mass spectrometry analysis.
Lin L; Zheng J; Yu Q; Chen W; Xing J; Chen C; Tian R
J Proteomics; 2018 Mar; 174():9-16. PubMed ID: 29278786
[TBL] [Abstract][Full Text] [Related]
10. Selecting Sample Preparation Workflows for Mass Spectrometry-Based Proteomic and Phosphoproteomic Analysis of Patient Samples with Acute Myeloid Leukemia.
Hernandez-Valladares M; Aasebø E; Selheim F; Berven FS; Bruserud Ø
Proteomes; 2016 Aug; 4(3):. PubMed ID: 28248234
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy in acute myeloid leukemia: current status and new insights from a proteomic perspective.
van Dijk AD; de Bont ESJM; Kornblau SM
Expert Rev Proteomics; 2020 Jan; 17(1):1-10. PubMed ID: 31945303
[No Abstract] [Full Text] [Related]
12. Proteomics of acute myeloid leukaemia: Cytogenetic risk groups differ specifically in their proteome, interactome and post-translational protein modifications.
Balkhi MY; Trivedi AK; Geletu M; Christopeit M; Bohlander SK; Behre HM; Behre G
Oncogene; 2006 Nov; 25(53):7041-58. PubMed ID: 16732326
[TBL] [Abstract][Full Text] [Related]
13. Preservation Method and Phosphate Buffered Saline Washing Affect the Acute Myeloid Leukemia Proteome.
Wangen R; Aasebø E; Trentani A; Døskeland SO; Bruserud Ø; Selheim F; Hernandez-Valladares M
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29351208
[TBL] [Abstract][Full Text] [Related]
14. Mass spectrometry based proteomics profiling as diagnostic tool in oncology: current status and future perspective.
Findeisen P; Neumaier M
Clin Chem Lab Med; 2009; 47(6):666-84. PubMed ID: 19445650
[TBL] [Abstract][Full Text] [Related]
15. Prognostic hallmarks in AML.
Clarke MA; Fisher J
Nat Biomed Eng; 2019 Nov; 3(11):847-849. PubMed ID: 31705121
[No Abstract] [Full Text] [Related]
16. Biomarker discovery in mass spectrometry-based urinary proteomics.
Thomas S; Hao L; Ricke WA; Li L
Proteomics Clin Appl; 2016 Apr; 10(4):358-70. PubMed ID: 26703953
[TBL] [Abstract][Full Text] [Related]
17. Construction of protein profile classification model and screening of proteomic signature of acute leukemia.
Xu Y; Zhuo J; Duan Y; Shi B; Chen X; Zhang X; Xiao L; Lou J; Huang R; Zhang Q; Du X; Li M; Wang D; Shi D
Int J Clin Exp Pathol; 2014; 7(9):5569-81. PubMed ID: 25337199
[TBL] [Abstract][Full Text] [Related]
18. Perseus: A Bioinformatics Platform for Integrative Analysis of Proteomics Data in Cancer Research.
Tyanova S; Cox J
Methods Mol Biol; 2018; 1711():133-148. PubMed ID: 29344888
[TBL] [Abstract][Full Text] [Related]
19. Targeted mass spectrometry approaches for protein biomarker verification.
Meng Z; Veenstra TD
J Proteomics; 2011 Nov; 74(12):2650-9. PubMed ID: 21540133
[TBL] [Abstract][Full Text] [Related]
20. Protein Post-Translational Modification Crosstalk in Acute Myeloid Leukemia Calls for Action.
Hernandez-Valladares M; Wangen R; Berven FS; Guldbrandsen A
Curr Med Chem; 2019; 26(28):5317-5337. PubMed ID: 31241430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
